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Abstract
Many clinical conditions including various types of cancers are complex and generally require invasive, laborious, 
expensive and time-consuming investigations for their diagnosis, treatment and follow-up. There is therefore a general 
need for exploring non-invasive markers in clinical medicine. Interleukin 8 (IL-8) is currently being applied in various 
subspecialties of medicine either for the purpose of rapid diagnosis or as a predictor of prognosis. Nevertheless, there is 
need for large-scale studies to substantiate accuracy and outcome. This article will summarize current evidence 
suggesting that Interleukin 8 (IL-8) may serve as a useful biomarker.
Background
Cancer is the second leading common cause of death.
Nearly, all types of cancer present diagnostic challenges
[1].Such diagnostic difficulty can delay treatment result-
ing in excess mortality and highlight the need for better
biomarker. In addition, infectious diseases are major
health care problem in developing countries. While there
are diagnostic tests available for infectious diseases, these
tests are laborious and time consuming [2].Due to delay
in diagnosis, physicians commonly start early broad-
spectrum antibiotics which may result in development of
multiple drug resistant strains of microorganisms. Thus
new biomarkers for disease must have a high sensitivity
and specificity.
Cytokines are important mediators of inflammation
and are associated with pathogenesis of many inflamma-
tory diseases. Cytokines are in clinical use as non-inva-
sive diagnostic markers, for disease prognosis and to
monitor treatment response. Interleukin 8 (IL-8) is a
member of the CXC chemokine subfamily [3] and is pro-
duced by blood cells and many types of tissues [4]. Neu-
trophil are major specific target for IL-8 action. Many
pathophysiological actions of IL-8 depend on activation
of neutrophils [4]. IL-8 is in routine use as a marker for
various clinical conditions (Table 1). In this article, we
will summarize some promising uses of Interleukin 8 (IL-
8) as a marker for diseases.
Marker for Urinary bladder cancer
Higher Interleukin 8 (IL-8) levels are present in patients
with invasive bladder cancer patients when compared to
individuals with superficial bladder cancer with 71%
assay sensitivity and specificity. In addition, urinary IL-8
levels can discriminate between superficial bladder can-
cer (SBC) and muscle invasive bladder cancer (MIBC) [5];
however, low assay sensitivity (62%) suggests urinary IL-8
is not a good marker for early diagnosis of bladder cancer,
but may serve as a predictor of prognosis [5].
Marker for Prostatitis
Increased IL-8 levels were detected in expressed prostatic
secretions (EPS) of chronic prostatitis (CP) [6]. In addi-
tion, higher IL-8 levels were detected in prostatic secre-
tions, ejaculate and serum from patients with latent CP
[7]. Thus increased expression of cytokines in EPS may
serve as a valuable diagnostic marker for CP. Other cytok-
ines such as IL-2 and IL-10 were also detected in EPS [6].
A panel of assay including cytokines detection in EPS can
serve as good marker for CP [6].
Marker for acute Pyelonephritis
Serum and urine IL-6 and IL-8 levels may be useful for
rapid detection of acute pyelonephritis in febrile children
[8]. This appears promising especially in pediatric cases
of urinary tract infections (UTI) which often present with
insufficient clinical manifestations thus making rapid
diagnosis of acute pyelonephritis extremely challenging.
Through rapid diagnosis and early treatment of acute
pyelonephritis, serious complications such as renal scar-
ring leading to hypertension and renal insufficiency can
be avoided. A positive correlation was shown between
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serum and urine levels of IL-6, IL-8, and C-reactive pro-
tein (CRP), WBC and fever in children with acute pyelo-
nephritis [8].IL-8 levels in serum has 81% sensitivity and
78% specificity for the diagnosis of acute pyelonephritis,
while, urine IL-8 levels showed 83% sensitivity and 83%
specificity [8].
Marker for Vesicoureteral reflux (VUR)
Vesicoureteral reflux (VUR) is a condition which predis-
poses children to recurrent UTI which may lead to hyper-
tension and renal insufficiency [9]. Currently, VUR is
diagnosed using expensive and invasive methods which
carry the risk of radiation exposure. Though, ultrasound
is non invasive technique but it has low sensitivity for
diagnosis of VUR [10,11]. Emmanouil et al found a con-
centration at 5pg/μmol, urine IL-8/creatinine concentra-
tion to be 88% sensitivity and 69% specificity for the
diagnosis of VUR [9]. Nevertheless, some conditions like
urinary tract infection (UTI), vaginitis and urinary tract
manipulation may result in increased level of IL-8. Since
the study is limited to infants, there is a need to extend it
to older children.
MOLECULAR IMAGING with radiolabelled IL-8
The safety of 99mTc-labeled IL-8 in humans and scintigra-
phy of 99mTc-labeled IL-8 in various experimental models
of diseases has been studied12. Injection of 99mTc-IL-8 is
well tolerated and 99mTc-labeled IL-8 scintigraphy is a
promising technique for diagnosis of many clinical condi-
tions [12].
Detection of pulmonary infections
99mTc-labeled IL-8 scintigraphy can be used to detect pul-
monary infections in experimental rabbit models of
aspergillosis, pneumococcal pneumonia and Escherichia
coli induced pneumonia. 99mTc- IL-8 is valuable for early
and excellent visualization of the extent and localization
of pulmonary infections. 99mTc- IL-8 is quick and easy to
prepare and has the advantage of short time span
between injection and imaging. 99mTc- IL-8 offers low
radiation burden and is associated with clear delineation
of infection foci [13].
Detection of Osteomyelitis
Rapid diagnosis of osteomyelitis is still challenging. Diag-
nostic changes appear only at advanced disease stages on
imaging films. Bone scanning and scintigraphic imaging
with  99mTc-methylene diphosphonate (MDP) are sensi-
tive, but have low specificities. This requires an imaging
system which can provide high specificity. Stephen et al
evaluated the role of 99mTc-labeled IL-8 in disease model
of osteomyelitis [14]. Based on their experimental results,
99mTc- IL-8 can be used to evaluate osteomyelitis with
good imaging quality and less radiation burden [14].
Other approaches for diagnosis include; anti-granulo-
cyte monoclonal antibody fragment labeled with Techne-
tium-99m which has recently been proposed for
Table 1: Promising use of interleukin 8 (IL-8) in various fields of medicine
Field proposed Usea Reference
Urology and Nephrology Marker for chronic prostatitis [6]
Marker for acute pyelonephritis [8]
Hematology Marker for non-Hodgkin's lymphoma [17]
Oncology Marker for urinary bladder cancer [5]
Therapeutic target to control cancer growth and metastasis [18]
Pediatrics Marker for nasocomial bacterial infections in neonatal intensive care unit (NICU) [15,16]
Marker for vesicoureteral reflux (VUR). [9]
Microbiology Detection of pulmonary infections [11]
Detection of osteomyelitis [12]
Nuclear Medicine 99mTc-labeled IL-8 scintigraphy for diagnosis of clinical conditions [10]
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diagnosis of osteomyelitis with high sensitivity and speci-
ficity [15].
Detection of Inflammatory bowel disease (IBD)
Radiolabeled leukocytes are routinely used for imaging
inflammatory bowel disease (IBD) but there are many
disadvantages associated with this procedure e.g., it is dif-
ficult to prepare [16]. Thus, there is a need for an agent
with good sensitivity that is easier to prepare. Stephen, et
al  studied the potential of IL-8 labeled 99mTc using
hydrazinonicotinamide (HYNIC) for imaging of inflam-
matory bowel disease (IBD) in rabbit model of acute coli-
tis [16]. They concluded that 99mTc-IL-8 is a promising
agent which can be prepared easily and provides excellent
imaging with high target-to-background ratios [16].
Crohn's disease (CD) associated mononuclear cell infil-
trate can be detected by 123l-lL2 scintigraphy [17].
Marker for Chorioamnionitis
Shimoya,  et al investigated IL-8 levels in cord sera of
babies to explore possible association with chorioamni-
onitis diagnosis [18]. They found that infected babies had
higher IL-8 titer as compared to non infected babies at
22-36 gestational weeks. They concluded that cord serum
IL-8 titer is a highly sensitive and specific diagnostic
marker as compared to other conventional markers avail-
able for diagnosis of chorioamnionitis[18].Among other
markers; C-reactive protein (CRP) estimation has 80%
sensitivity and specificity for early diagnosis of subclinical
chorioamnionitis[19].
Marker for nasocomial bacterial infections
Nasocomial bacterial infections are responsible for high
rate of mortality and morbidity in neonatal patients [20].
Routine investigations and tests used for evaluation of
infection are non-specific. There is therefore a need to
explore new markers which can detect infection at early
stages and can thus allow for immediate commencement
of antibiotic therapy after diagnosis to reduce high mor-
tality rate.
Axel, et al investigated the role of IL-8 as an early
marker for diagnosis of Nasocomial bacterial infec-
tions [20]. They found that combination of IL-8 and
C-reactive protein (CRP) is able to detect culture
proven nasocomial bacterial infection with 96% spec-
ificity. They proposed that this combination of mark-
ers is cost effective and reliable for early diagnosis of
nasocomial bacterial infections in neonates [20].
Joern, et al compared plasma levels of IL-8 with IL-6
to check their potential as a marker for infection in
neonatal intensive care unit (NICU) patients [21].
T h e y  c o n c l u d e d  t h a t  I L - 8  i s  a  m o r e  u s e f u l  m a r k e r
than IL-6 because it requires less sample volume and
less time than IL-6 determination [21].
Marker for non-Hodgkin's lymphoma (NHL)
There is high incidence of non-Hodgkin's lymphoma
(NHL) in western world especially in North America and
European countries since past many years [22-24]. There
are studies which evaluated the role of IL-8 as a diagnos-
tic marker for non-Hodgkin's lymphoma (NHL) [25]. Hye
lin, et al measured serum and urine IL-8 levels to check
the role in diagnosis of NHL [25]. Their studies indicate
t h a t  u r i n e  I L - 8 / C r  ( c r e a t i n i n e )  l e v e l  m a y  b e  u s e d  a s  a
diagnostic marker for NHL, but found no differences in
serum concentrations of IL-8 between NHL patients and
controls [25].
Role in cancer therapeutics
IL-8 has angiogenic, mitogenic and motogenic activities
[26]. There are studies that propose that IL-8 helps in
cancer progression [27]. IL-8 expression control may be a
valuable tool in designing new therapeutics for control of
cancer growth and metastasis. Therefore, further
r e s e a r c h  i s  w a r r a n t e d  t o  f u l l y  u n d e r s t a n d  t h e  m e c h a -
nisms of IL-8 expression [26].
Conclusions
Interleukin 8 (IL-8) is a promising marker for many clini-
cal conditions and currently being applied by various sub-
specialties of medicine either for the purpose of rapid
diagnosis or as a predictor of prognosis. Nevertheless, IL-
8 level increased as a result of many inflammatory condi-
tions, so careful interpretation of IL-8 level is required to
make correlation with desired clinical condition's diagno-
sis or prognosis. A panel consisting of more then one bio-
marker including IL-8 will be promising diagnostic and
prognostic approach for many clinical disorders. Never-
theless, large-scale studies are needed to substantiate the
accuracy and outcome of IL-8's usefulness and effective-
ness as a biomarker.
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